Thermo Fisher (NYSE: TMO) VP granted options and performance shares
Rhea-AI Filing Summary
Thermo Fisher Scientific VP & Chief Accounting Officer Joseph R. Holmes reported equity awards tied to performance-based stock programs. He acquired 985 stock options at an exercise price of $0.0000 per option and 433 shares of common stock as a performance-based restricted stock unit award.
An additional 337 shares of common stock were reported as an adjustment to the final tranche of a 2023 performance-based restricted stock unit award after a 15% reduction in the payout, which resulted in 6 fewer shares than previously reported. The new option grant vests in four equal annual installments beginning on February 28, 2027, and the 2025 performance-based award vests in thirds on February 28, 2026, 2027, and 2028, with the last third still subject to long-term total shareholder return performance.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 985 | $0.00 | -- |
| Grant/Award | Common Stock | 433 | $0.00 | -- |
| Grant/Award | Common Stock | 337 | $0.00 | -- |
Footnotes (1)
- Shares represent a performance-based restricted stock unit award granted on February 19, 2025. The Company's Compensation Committee determined on February 25, 2026, that the performance criteria related to this award were satisfied. One-third of the shares vest on February 28, 2026 and 2027. The remaining one-third will vest on February 28, 2028, and is subject to adjustment (positive or negative) for long-term performance which is based on the comparison of the Company's total shareholder return compound annual growth rate ("CAGR") to the total shareholder return CAGR of each of the companies in the peer group, as specified within the award agreement, over the measurement period starting on January 1, 2025, through to December 31, 2027. Shares represent an adjustment to the final tranche of a performance-based restricted stock unit award granted on February 22, 2023. On February 25, 2026, the Compensation Committee certified a 15% reduction based on the Company's relative TSR performance over the three-year measurement period, resulting in 6 fewer shares than previously reported. The option vests in four equal annual installments beginning on February 28, 2027.